MedTrace Logo

Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

NCT07403552 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.

Conditions

  • Healthy

Interventions

DRUG

NSHO-101

Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days

Sponsors & Collaborators

  • Ensho Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-03-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07403552 on ClinicalTrials.gov